CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its third quarter 2025 financial results and provide a business update on Thursday, November 13, after the market close. The Company does not intend to host a conference call.
About Spero Therapeutics
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections with high unmet need. For more information, visit www.sperotherapeutics.com
Spero Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@sperotherapeutics.com
Spero Media Inquiries:
media@sperotherapeutics.com

| Nov-12 | |
| Nov-10 | |
| Nov-04 | |
| Nov-02 | |
| Oct-26 | |
| Oct-15 | |
| Oct-02 | |
| Sep-03 | |
| Sep-02 | |
| Aug-13 | |
| Aug-12 | |
| Aug-05 | |
| Aug-04 | |
| Jul-27 | |
| Jul-15 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite